Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis: A Randomized Single-Blind Placebo-Controlled Trial at AIMS, Hyderabad, Pakistan

NCT07521332 is registered in ClinicalTrials.gov with Asian Institute Of Medical Sciences as lead sponsor.

NCT NCT07521332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07521332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis: A Randomized Single-Blind Placebo-Controlled Trial at AIMS, Hyderabad, Pakistan
Lead sponsor
Asian Institute Of Medical Sciences
Phase
Phase 4
Overall status
Recruiting
Start date
April 1, 2026
Completion date
April 1, 2028
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascites, cirrhosis, esophageal and gastric varices, hepatic encephalopathy, portal hypertension, portal vein thrombosis